At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Multicenter Clinical Trial of O6Benzylguanine and Topical Carmustine in the Treatment of Refractory Early-Stage (IA-IIA) Cutaneous T-Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Carmustine, Laboratory Biomarker Analysis, and 1 other intervention for Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma and 2 related conditions. Completed, enrolled 17 participants across 4 sites.
Detailed Summary
This phase I/II trial studies the side effects and best dose of carmustine when given together with O6-benzylguanine and to see how well they work in treating patients with stage IA-IIA cutaneous T-cell lymphoma. Drugs used in chemotherapy, such as carmustine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. O6-benzylguanine may help carmustine work better by making cancer cells more sensitive to the drug. Giving O6-benzylguanine with carmustine may kill more cancer cells.
Study Details
Timeline
Interventions
Applied topically
Correlative studies
Given IV